Jianjie Ma, Ph.D.
Dr. Jianjie Ma, Ph.D., is the Founder and President of TRIM-edicine. He holds the Karl P. Klassen Chair of Thoracic Surgery in the Department of Surgery at The Ohio State University (OSU). He is an OSU Davis Heart Lung Research Institute Investigator and serves on the advisory committee of the Center for Regenerative Medicine and Cell- Based Therapies in the College of Medicine. Dr. Ma obtained his bachelor’s degree in Physics from Wuhan University in China and Ph.D. in Physiology and Biophysics at Baylor College of Medicine. He serves on the editorial board of several major scientific journals and has authored or co-authored over 150 articles in peer-reviewed scientific journals. He was an Established Investigator of the American Heart Association, and has frequently served as study section members for the National Institutes of Health. His research interests are in gene discovery and protein therapy in geriatric medicine, tissue repair, muscular dystrophy, cardiovascular disease, and cancer biology.
Founder and President
Email : email@example.com
Tao Tan, M.D., Ph.D.
Tao Tan is the Vice President of Research and Development at TRIM-edicine. She obtained her M.D. training in China and received a Ph.D. degree from the Graduate Program in Physiology and Integrative Biology at the Rutgers University – Robert Wood Johnson Medical School, and joined TRIM-edicine in 2009. She has co-authored over 30 publications in areas of molecular medicine, and is recipient of an Oversea Young Investigator Award from China. Dr. Tan leads the Research and Development effort at TRIM-edicine, as well as the management of the company.
Email : firstname.lastname@example.org
Scientific Advisory Board
Noah Weisleder, Ph.D.
Noah Weisleder received his B.S. in Biotechnology from Worcester Polytechnic Institute with Distinction and a Ph.D. in Cell Biology from Baylor College of Medicine. He conducted his postdoctoral studies at Robert Wood Johnson Medical School where joined the faculty as Assistant Professor in the Department of Physiology and Biophysics. Currently, Dr. Weisleder is an Associate Professor of Physiology and Cell Biology at The Ohio State University and an Investigator in the Davis Heart and Lung Research Institute. Dr. Weisleder has published numerous peer-reviewed publications or book chapters in the fields of muscle physiology, cardiovascular disease, cytoskeletal dynamics, membrane repair and cellular calcium homeostasis in normal physiology and disease states. He has chaired sessions at national and international meetings on muscle physiology and metabolism, and been invited to present his research at several international conferences. Dr. Weisleder has received several honors, including a Fellowship from the American Heart Association, a Pathway to Independence Award from the National Institutes of Health and the Kauffman Foundation Outstanding Postdoctoral Entrepreneur Award. Additionally, he is an inventor on multiple US and international patents that became the basis for formation of TRIM-edicine where Dr. Weisleder is Co-Founder.
Peter Mohler, Ph.D.
Dr. Mohler is currently the Director of the Davis Heart & Lung Research Institute (“DHLRI”) and Associate Dean for Research at the Ohio State University Medical Center. He received his Ph.D. in Molecular Physiology from the University of North Carolina at Chapel Hill in 2000. Prior to coming to work at OSU, he conducted his post-doctoral research at the Howard Hughes Medical Institute at Duke University and was a faculty member at the Vanderbilt University Medical Center and the University of Iowa. In 2011, he was recruited to direct the DHLRI at Ohio State University, which is one of the world’s top cardiovascular research facilities. Over 500 investigators and staff work here translating basic discoveries in heart and lung research into clinical applications. His research has been funded by the National Science Foundation, U.S. National Institutes of Health, Pew Charitable Trust, Sandler Foundation, Fondation LeDucq, and the American Heart Association. Dr. Mohler’s Personal Research focuses on the molecular mechanisms underlying ion channel and transporter targeting in cardiac and other excitable cells.
William T. Abraham, M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.
William T. Abraham is Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University College of Medicine. Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts. He completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology at the University of Colorado Health Sciences Center. Dr. Abraham spends the majority of his clinical time managing heart failure patients in the inpatient and outpatient settings. Dr. Abraham has been recognized as one of the “Best Doctors in America” for twelve consecutives years and has been ranked among the top 10% of physicians nationally in patient satisfaction. Dr. Abraham’s research interests include hemodynamic and neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure. Dr. Abraham has authored more than 700 original papers, abstracts, book chapters, and review articles. He has also received grants from the National Institutes of Health, American College of Cardiology, and Aetna Quality Care Foundation and has participated as a site Principal Investigator in more than 100 multicenter clinical drug and device trials. As an essential scientific advisory board member, Dr. Abraham will provide leadership for both the pre-clinical and clinical studies related to translational application of MG53 for unmet medical need.
Elizabeth John, Ph.D.
Dr. John has over twenty years of experience in pharmaceutical development. She also has extensive in project management and regulatory affairs. She has worked on many IND applications of drugs and biologics and has interacted with US, Canadian, New Zealand and Australian regulatory authorities. She was the Manager of Product Development and Quality Control at Neorx Corporation in Seattle where she played a key role in the development of the skeletal targeted radiotherapeutic product, Dr. John served as the Director of Pharmaceutical Development, NewBiotics, Inc and Celmed Biosciences, Montreal, the company that acquired NewBiotics in 2004. She joined Proacta, Inc. in 2005 as Vice President of Pharmaceutical Development / Regulatory Affairs and was responsible for writing and filing the company’s first IND.Dr. John joined Centegen, Inc. in 2007 as the Vice President of Drug Development and was responsible for managing Centegen’s non-clinical activities. She served as V.P., CMC at EnzymeRx, which was acquired by 3SBio in 2010. Dr. John received her Ph.D. in Chemistry from Rutgers University and conducted her post-doctoral research at Purdue University followed by 3 years as Research Associate at Thomas Jefferson Hospital.
Company IP Consultant
Bryan Zerhusen, J.D., Ph.D.
As an partner with Locke Lord LLP, Dr. Zerhusen’s practice includes all aspects of patent and trademark prosecution, licensing, due diligence, clearance and patentability opinions, and patent infringement litigation support concentrating on scientific/medical devices, biotechnology, pharmaceuticals, and chemicals. Dr. Zerhusen’s clients include individual researchers, biotech companies, universities, as well as large chemical and pharmaceutical companies. Dr. Zerhusen’s prior scientific training includes a postdoctoral fellowship at Case Western Reserve University, which was focused on molecular and physiological origins of cystic fibrosis, as well as a number of years as a Research Scientist for a mid-sized biopharmaceutical company where he utilized genomic and proteomic techniques to identify and characterize therapeutic candidates/targets over all major disease areas.